Fundraising Fox
Tarveda Therapeutics
Watertown, US · Founded 2011 · Delaware corporation · 5 employees on LinkedIn · 3 known investors
Find your way into Tarveda Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
325 people can intro you to Leila
Ask Brian J. Roberts to introduce you to Leila Alland
You →Brian · together at Tarveda Therapeutics →Leila
96 people can intro you to Robert
Ask Jamie Chen to introduce you to Robert Langer
You →Jamie · together at Lyndra →Robert
Sign up to find every way you can get introduced to Tarveda Therapeutics
- Your email: who you already know at Tarveda Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Tarveda Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
Tarveda Therapeutics was founded in 2011 by Omid Farokhzad, Robert S. Langer, Jr., and Robert S. Langer.
RS
RS
AJ
Andrew J. FromkinExecutive
LA
Leila AllandChief Medical Officer2016–2018Leila Alland is an MD with extensive experience in oncology drug development at major pharmaceutical companies including AstraZeneca, Bristol-Myers Squibb, Novartis, and Schering-Plough, where she held leadership roles in clinical development and served as Chief Medical Officer at PMV Pharma, Affimed, and Tarveda Therapeutics. She holds a BA from the University of Pennsylvania and an MD from New York University, completed fellowship training in hematology/oncology at Memorial Sloan Kettering Cancer Center, and served as faculty at Albert Einstein College of Medicine.
Board
JB
James BarrettBoard director
FT
Frank TortiBoard director
NK
Nilesh KumarBoard director
AS
EM
Edwin M. KaniaBoard director
DA
Dennis AusielloBoard director
Investors · 3
+ND Capitallisted by +ND CapitalWoodside · $540K – $5.4M
How we know: +ND Capital's portfolio page · a partner's Signal profile · funding news · Not right? Tell us
Kendall Capital PartnersinferredBostonvia Robert Langer · board
How we know: board seat on SEC Form D · Not right? Tell us
New Enterprise Associates (NEA)reportedMenlo Park · $200K – $40M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$103.6M disclosed across 6 rounds · 2014–2021
▶$6MraisedSep 2021 · 1 investors · BiotechnologyRule 506(b)
▶$6MraisedSep 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aymeric SallinDirector
- Michael MetzgerDirector
- Brian RobertsExecutive Officer, Director
- Nilesh KumarDirector
- Dennis AusielloDirector
- Guido MagniDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedDec 2020 · 8 investors · BiotechnologyRule 506(b)
▶$15MraisedDec 2020 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nilesh KumarDirector
- Guido MagniDirector
- Michael MetzgerDirector
- Aymeric SallinDirector
- Brian RobertsExecutive Officer
- Dennis AusielloDirector
- Offering amount
- $15.4M
- Amount sold
- $15M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.6MraisedDec 2019 · 13 investors · BiotechnologyRule 506(b)
▶$13.6MraisedDec 2019 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael MetzgerDirector
- Aymeric SallinDirector
- Robert LangerDirector
- Nilesh KumarDirector
- Guido MagniDirector
- Omid FarokhzadDirector
- Andrew J. FromkinExecutive Officer, Director
- Dennis AusielloDirector
- Offering amount
- $13.6M
- Amount sold
- $13.6M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$38MraisedFeb 2017 · 8 investors · BiotechnologyRule 506(b)
▶$38MraisedFeb 2017 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aymeric SallinDirector
- Andrew FromkinExecutive Officer, Director
- Robert S. LangerDirector, Promoter
- Leila AllandExecutive Officer
- Edwin M. KaniaDirector
- James BarrettDirector
- Dennis AusielloDirector
- Nilesh KumarDirector
- Richard WoosterExecutive Officer
- Omid C. FarokhzadDirector, Promoter
- Frank TortiDirector
- Offering amount
- $38M
- Amount sold
- $38M
- Finders' fees
- $720K
- Proceeds to insiders
- $2.5M
- Placement agents
- MTS Securities, LLC
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedFeb 2017 · 7 investors · BiotechnologyRule 506(b)
▶$30MraisedFeb 2017 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew J. FromkinExecutive Officer, Director
- Omid FarokhzadDirector
- James BarrettDirector
- Frank TortiDirector
- Robert S. Langer, Jr.Director
- Leila AllandExecutive Officer
- Nilesh KumarDirector
- Dennis AusielloDirector
- Richard WoosterExecutive Officer
- Aymeric SallinDirector
- Guido MagniDirector
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1000KraisedMar 2014 · 1 investors · BiotechnologyRule 506(b)
▶$1000KraisedMar 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Omid C. FarokhzadDirector
- Robert S. LangerDirector
- James BarrettDirector
- Richard WoosterExecutive Officer
- Peter Barton HuttDirector
- Aymeric SallinDirector
- Edwin M. KaniaDirector
- Offering amount
- $1000K
- Amount sold
- $1000K
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Tarveda Therapeutics went on to found or lead other companies.
Frequently asked questions
- Who founded Tarveda Therapeutics?
- Tarveda Therapeutics was founded by Omid Farokhzad, Robert S. Langer, Jr., Robert S. Langer in 2011.
- Who are Tarveda Therapeutics's investors?
- Tarveda Therapeutics's investors include +ND Capital, Kendall Capital Partners, New Enterprise Associates (NEA).
- How much funding has Tarveda Therapeutics raised?
- Tarveda Therapeutics has disclosed $103.6M raised across 6 rounds.
- Where is Tarveda Therapeutics headquartered?
- Tarveda Therapeutics is headquartered in Watertown, US.